Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628893 | 0.87 | CYP3A4 (0.66) | MAPTCYP3A4KCNH2GSK3BNPC1 | |
| SCHEMBL23629019 | 0.84 | GSK3B (0.55) | MAPTGSK3BNPC1RAB9ACSNK1D | |
| SCHEMBL23628959 | 0.83 | GSK3B (0.54) | MAPTGSK3BNPC1RAB9ACSNK1D | |
| SCHEMBL23629027 | 0.81 | GSK3B (0.52) | MAPTGSK3BNPC1RAB9ACSNK1D | |
| SCHEMBL145671 | 0.80 | NPC1 (0.67) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30189826 | 0.80 | NPC1 (0.67) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1980717 | 0.78 | PIK3CA (0.66) | MAPTNPC1RAB9ASCDMEN1 | |
| SCHEMBL16689961 | 0.76 | KMT2A (0.67) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL27882017 | 0.76 | MAPT (0.67) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL31550075 | 0.75 | SMN1; SMN2 (0.53) | MAPTGSK3BNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | UNIVERZA V LJUBLJANI (SI) | 2021-10-21 | — | — | US | disclosed |
| EP-3847172-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | Univerza v Ljubljani (SI) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOP1, TOP2A, TOP2B | MAPT 2932/4885CYP3A4 643/4885KCNH2 4232/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | MAPT 2543/4885CYP3A4 587/4885KCNH2 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.